Answers are grounded in this paper and cite their sources.
Study reveal lower mortality in cancer patients with diabetes using SGLT2 inhibitors, suggesting potential benefits.
SGLT2i was associated with lower all-cause mortality in patients diagnosed with diabetes and cancer. Randomized clinical trials are needed to confirm these findings and explore the underlying mechanism.
No takes yet. Share an insight, caveat, or question.
Perelman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: